Prestige Consumer Healthcare Inc banner

Prestige Consumer Healthcare Inc
F:PBV

Watchlist Manager
Prestige Consumer Healthcare Inc Logo
Prestige Consumer Healthcare Inc
F:PBV
Watchlist
Price: 49.2 EUR 2.5%
Market Cap: €2.5B

EV/OCF

13.5
Current
27%
Cheaper
vs 3-y average of 18.5

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
13.5
=
Enterprise Value
€4.3B
/
Operating Cash Flow
$276.6m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
13.5
=
Enterprise Value
€4.3B
/
Operating Cash Flow
$276.6m

Valuation Scenarios

Prestige Consumer Healthcare Inc is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (18.5), the stock would be worth €67.53 (37% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+37%
Average Upside
25%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 13.5 €49.2
0%
3-Year Average 18.5 €67.53
+37%
5-Year Average 17.7 €64.66
+31%
Industry Average 14.4 €52.54
+7%
Country Average 16.7 €60.86
+24%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
US
Prestige Consumer Healthcare Inc
F:PBV
2.7B EUR 13.5 14.7
US
Eli Lilly and Co
NYSE:LLY
853.2B USD 52.7 41.3
US
Johnson & Johnson
NYSE:JNJ
544.6B USD 23.3 25.9
CH
Roche Holding AG
SIX:ROG
248.4B CHF 14.9 19.6
UK
AstraZeneca PLC
LSE:AZN
225.8B GBP 22 29.3
CH
Novartis AG
SIX:NOVN
222.8B CHF 15.5 20
US
Merck & Co Inc
NYSE:MRK
278.5B USD 18.9 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.1 10.8
US
Pfizer Inc
NYSE:PFE
155.3B USD 17.4 20
US
Bristol-Myers Squibb Co
NYSE:BMY
119.6B USD 10.8 17
P/E Multiple
Earnings Growth PEG
US
Prestige Consumer Healthcare Inc
F:PBV
Average P/E: 21.4
14.7
4%
3.7
US
Eli Lilly and Co
NYSE:LLY
41.3
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
25.9
8%
3.2
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.3
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
20
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1

Market Distribution

Lower than 70% of companies in the United States of America
Percentile
30th
Based on 9 518 companies
30th percentile
11.7
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Prestige Consumer Healthcare Inc
Glance View

Prestige Consumer Healthcare Inc. has carved out its niche in the competitive realm of over-the-counter healthcare products with a distinct flair. Born out of a series of insightful acquisitions and strategic brand cultivations, the company has crafted a portfolio that caters to a broad spectrum of consumer health needs. It offers an expansive range of products, from well-known pain relievers and eye care items to gastrointestinal treatments and women’s health solutions. The cornerstone of Prestige's success lies in its acute understanding of consumer demand and its agile response to market trends. By developing and acquiring brands that are established household names—such as Clear Eyes, Chloraseptic, and Dramamine—the firm has effectively secured a reliable revenue stream. Each brand, while under the corporate umbrella of Prestige, thrives on its ability to resonate with consumers who seek trustworthy, easily accessible remedies. Central to Prestige’s business model is its adeptness at maintaining and enhancing brand equity. Through a blend of focused marketing strategies and disciplined cost management, the company ensures consistent visibility and availability of its products across key retail channels, including mass merchandisers, drug retailers, and e-commerce. Prestige's skillful navigation of the marketplace allows it to capitalize on scale economies and maintain healthy margins. Each product in its portfolio is not only a testament to its commitment to quality and efficacy but also to its strategic foresight in addressing the ever-evolving healthcare challenges faced by consumers. In essence, Prestige Consumer Healthcare Inc. thrives by blending astute brand management with a keen focus on consumer health trends, ensuring its position as a formidable player in the healthcare industry.

PBV Intrinsic Value
64.49 EUR
Undervaluation 24%
Intrinsic Value
Price €49.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett